Health Care Deal News, March 18, 2013 - Clinical Contract Research Organizations are Seeing some M&A Action Recently, Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) has Acquired the Rights to Ceftolozane

 

Brought to you by www.DealSearchOnline.com
 

March 18, 2013 Issue:

 

Recent Health Care M&A Deals

BEHAVIORAL HEALTH CARE

Acquirer

Target

Price

 Recovery and Rehabilitation Partnership Ltd.

 Nelson House

 $10.4 million

BIOTECHNOLOGY

Acquirer

Target

Price

 Rxi Pharmaceutical Corporation

 OPKO Health's RNAi-related assets

 $14 million

HOSPITALS

Acquirer

Target

Price

 Carolinas HealthCare System

 Cleveland County HealthCare System

 $101 million

PHARMACEUTICALS

Acquirer

Target

Price

 Cubist Pharmaceuticals, Inc.

 Rights to Ceftolozane

$25 million

NeuroVive Pharmaceutical AB

Portfolio of novel cyclophilin inhibitors

N/A

 

HCC Best Practices for Proactive Medical Management
March 18-19, 2013 - Sheraton Music City Hotel - Nashville, TN
We are pleased to announce our 4th Annual HCC Best Practices conference. This conference will build on the success of the 2011 and 2012 conferences while providing practical, timely updates to help you continue to evolve your medical management practices with sound HCC coding.

www.opalevents.org/trk/hccb1301.html

 

Service Deal of the Week
Clinical contract research organizations are seeing some M&A action recently. So far this month, two CROs have changed hands, although no prices were given. The first was for Harrison Clinical Research Group of Munich, Germany, which was purchased by San Diego-based Synteract, another CRO that is a portfolio company of Gryphon Investors. The two companies are forming a multinational CRO named SynteractHCR, with offices in 16 countries. The second deal was a strategic acquisition of ClinStar, LLC, which manages Phase 1 through 4 trials in the Russian Federation, Ukraine, Belarus and the Baltic States. The buyer was PRA, a Raliegh, North Carolina-based CRO with facilities in more than 80 countries.....Want to read more news? Click here for a free trial to The Health Care M&A Information Source and download the current issue today.

 

Charted Territory
Despite the ongoing uproar over the 2.3% excise tax that went into effect on January 1, 2013, medical devices are still a busy segment for M&A activity. So far this year, we’ve counted 17 announced deals for all manner of medical devices, developers and manufacturers. While not all deals came with prices, the current dollar volume totals $704.5 million. And we haven’t even reached the end of Q1:13.

 

Top Five Medical Devices Deals in 2013, through March 15, 2013

Target

Acquirer

Price

HemoCue

Radiometer Medical ApS

$300,000,000

Trauson Holdings Co.

Stryker Corporation

$98,500,000

Lifecodes unit

Immucor, Inc.

$85,000,000

Ultrasonix Medical Corp.

Analogic Corporation

$83,000,000

NDS Surgical Imaging

GSI Group, Inc.

$82,500,000

Want to read more news? Click here for a free trial to The Health Care M&A Information Source and download the current issue today

 

Technology Deal of the Week
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) has acquired the rights to ceftolozane, a potential first-line intravenous therapy to treat complicated intra-abdominal infections and urinary tract infections, in certain Asia-Pacific and Middle East territories from Astellas Pharma Inc. (Tokyo: 4503). Cubist paid $25 million in cash, and now owns the worldwide rights to the drug, which is currently part of two Phase 3 trials in combination with taxobactam.....Want to read more news? Click here for a free trial to The Health Care M&A Information Source and download the current issue today.

 

In the Pipeline
On March 1, diagnostics giant Alere Inc. (NYSE: ALR) announced it had received a grant from the Bill and Melinda Gates Foundation to develop a tuberculosis assay and support its point-of-care HIV test. The foundation is donating $21.6 million for the TB program and offering below-market debt financing of up to $20.6 million to support Alere’s manufacturing efforts at its facilities in Jena, Germany for both the point-of-care TB Nucleic Acid Test and the HIV Viral Load Test which are in the final stages of development. Alere has committed to make these diagnostics available at an affordable price to people in need in developing countries.....Want to read more news? Click here for a free trial to The Health Care M&A Information Source and download the current issue today.

 

NEW - The Health Care Services Acquisition Report, 19th Edition - Preorder Today!
Deals have been made. The 2013 Health Care Services Acquisition Report contains private deals in this market that are too small to make it into the financial press. Take advantage of our limited 2-for-1 offer - preorder The 2013 Health Care Services Acquisition Report by March 31st and receive The 2012 Health Care Services Acquisition Report FREE ($595 value)! Now that’s a recession resistant deal. Go to http://www.levinassociates.com/hardescription or call 800-248-1668 to preorder today!

 
Conference Calendar...Click here to see more